| Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions JR Gamble, J Drew, L Trezise, A Underwood, M Parsons, L Kasminkas, ... Circulation research 87 (7), 603-607, 2000 | 602 | 2000 |
| From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity NL Trevaskis, LM Kaminskas, CJH Porter Nature Reviews Drug Discovery 14 (11), 781-803, 2015 | 281 | 2015 |
| The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly l-Lysine Dendrimers LM Kaminskas, BJ Boyd, P Karellas, GY Krippner, R Lessene, B Kelly, ... Molecular pharmaceutics 5 (3), 449-463, 2008 | 178 | 2008 |
| Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties LM Kaminskas, BJ Boyd, CJH Porter Nanomedicine 6 (6), 1063-1084, 2011 | 155 | 2011 |
| A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems LM Kaminskas, VM McLeod, BD Kelly, G Sberna, BJ Boyd, M Williamson, ... Nanomedicine: Nanotechnology, Biology and Medicine 8 (1), 103-111, 2012 | 142 | 2012 |
| Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats BJ Boyd, LM Kaminskas, P Karellas, G Krippner, R Lessene, CJH Porter Molecular pharmaceutics 3 (5), 614-627, 2006 | 140 | 2006 |
| Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-l-lysine Dendrimers LM Kaminskas, BD Kelly, VM McLeod, BJ Boyd, GY Krippner, ED Williams, ... Molecular pharmaceutics 6 (4), 1190-1204, 2009 | 139 | 2009 |
| Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy LM Kaminskas, VM McLeod, GM Ryan, BD Kelly, JM Haynes, ... Journal of Controlled Release 183, 18-26, 2014 | 134 | 2014 |
| Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation LM Kaminskas, VM McLeod, CJH Porter, BJ Boyd Molecular pharmaceutics 9 (3), 355-373, 2012 | 133 | 2012 |
| Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products PC Burcham, LM Kaminskas, FR Fontaine, DR Petersen, SM Pyke Toxicology 181, 229-236, 2002 | 130 | 2002 |
| PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats LM Kaminskas, J Kota, VM McLeod, BD Kelly, P Karellas, CJH Porter Journal of Controlled Release 140 (2), 108-116, 2009 | 123 | 2009 |
| New developments in dry powder pulmonary vaccine delivery T Sou, EN Meeusen, M de Veer, DAV Morton, LM Kaminskas, ... Trends in biotechnology 29 (4), 191-198, 2011 | 120 | 2011 |
| The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules T Sou, LM Kaminskas, TH Nguyen, R Carlberg, MP McIntosh, DAV Morton European Journal of Pharmaceutics and Biopharmaceutics 83 (2), 234-243, 2013 | 109 | 2013 |
| Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker LM Kaminskas, BD Kelly, VM McLeod, G Sberna, DJ Owen, BJ Boyd, ... Journal of controlled release 152 (2), 241-248, 2011 | 107 | 2011 |
| Targeting the lymphatics using dendritic polymers (dendrimers) LM Kaminskas, CJH Porter Advanced drug delivery reviews 63 (10-11), 890-900, 2011 | 98 | 2011 |
| Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice LM Kaminskas, SM Pyke, PC Burcham Journal of Pharmacology and Experimental Therapeutics 310 (3), 1003-1010, 2004 | 92 | 2004 |
| Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent GM Ryan, LM Kaminskas, BD Kelly, DJ Owen, MP McIntosh, CJH Porter Molecular Pharmaceutics 10 (8), 2986-2995, 2013 | 82 | 2013 |
| Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse … LM Kaminskas, VM McLeod, BD Kelly, C Cullinane, G Sberna, ... Molecular pharmaceutics 9 (3), 422-432, 2012 | 70 | 2012 |
| Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity PC Burcham, FR Fontaine, LM Kaminskas, DR Petersen, SM Pyke Molecular pharmacology 65 (3), 655-664, 2004 | 69 | 2004 |
| Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers LM Kaminskas, BD Kelly, VM McLeod, G Sberna, BJ Boyd, DJ Owen, ... Molecular pharmaceutics 8 (2), 338-349, 2011 | 64 | 2011 |
